The incidence of Acute Coronary Syndrome (ACS) is on the rise, making it a pressing global health concern. In Malaysia, cardiovascular diseases have consistently ranked as the leading cause of mortality for several decades, with cardiovascular disease contributing significantly to the non-communicable disease-related deaths. Statins, a class of prescription drugs designed to lower cholesterol levels, play a pivotal role in preventing ACS. However, they are associated with statin-related side effects, primarily muscle-related issues, including pain, lethargy, weakness, and myopathy. Observational studies have reported muscle problems in a substantial proportion of patients, ranging from 10% to 30%, while randomized controlled trials have indicated a lower but still significant incidence, affecting up to 5% of patients. Given the increasing significance of ACS, it is crucial to critically identify effective management and treatment strategies for this condition